Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells.

ABSTRACT:

Background

Therapeutic options for CD19⁺ relapses after anti-CD19 CAR-T cells are still debated; second infusion of anti-CD19 CAR-T cells, therapeutic antibodies, or targeted therapies can be discussed. Here, we explore the immunophenotyping and lysis sensitivity of CD19⁺ ALL relapse after anti-CD19 CAR-T cells and propose different therapeutic options for such a high-risk disease.

Methods

Cells from successive B-ALL relapses from one patient were collected. A broad immunophenotype analysis was performed. ⁵¹Cr cytotoxic assays, and long-term killing assays were conducted using T-cell effectors that are capable of cytotoxicity through three recognition pathways: antibody-dependent cell-mediated cytotoxicity (ADCC), anti-CD19 CAR-T, and TCR.

SUBMITTER: Grain A 

PROVIDER: S-EPMC9953531 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature